Toggle navigation
Login
Toggle navigation
JavaScript is disabled for your browser. Some features of this site may not work without it.
The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling
QMRO Home
William Harvey Research Institute
Centre for Translational Medicine & Therapeutics
The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling
QMRO Home
William Harvey Research Institute
Centre for Translational Medicine & Therapeutics
The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling
Browse
All of QMRO
Communities & Collections
By Issue Date
Authors
Titles
Subjects
This Collection
By Issue Date
Authors
Titles
Subjects
Administrators only
Login
Statistics
Most Popular Items
Statistics by Country
Most Popular Authors
The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling
View/
Open
Accepted version (9.754Mb)
Accepted version (1.695Mb)
Volume
30
Pagination
33 - 49
DOI
10.1681/ASN.2018020209
Journal
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Issue
1
ISSN
1046-6673
Metadata
Show full item record
Authors
Andrikopoulos, P; Kieswich, J; Pacheco, S; Nadarajah, L; Harwood, SM; O'Riordan, CE; Thiemermann, C; Yaqoob, MM
URI
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54661
Collections
Centre for Translational Medicine & Therapeutics
[844]
Copyright statements
American Society of Nephrology